TY - JOUR AU - Parkin, D. M. AU - Bray, F. AU - Ferlay, J. AU - Pisani, P. PY - 2005 DA - 2005// TI - Global cancer statistics, 2002 JO - CA Cancer J Clin VL - 55 UR - https://doi.org/10.3322/canjclin.55.2.74 DO - 10.3322/canjclin.55.2.74 ID - Parkin2005 ER - TY - JOUR AU - Sargent, D. J. AU - Wieand, H. S. AU - Haller, D. G. AU - Gray, R. AU - Benedetti, J. K. AU - Buyse, M. PY - 2005 DA - 2005// TI - Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.01.6071 DO - 10.1200/JCO.2005.01.6071 ID - Sargent2005 ER - TY - JOUR AU - Bokemeyer, C. AU - Bondarenko, I. AU - Makhson, A. AU - Hartmann, J. T. AU - Aparicio, J. AU - Braud, F. PY - 2009 DA - 2009// TI - Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.20.8397 DO - 10.1200/JCO.2008.20.8397 ID - Bokemeyer2009 ER - TY - JOUR AU - Cutsem, E. AU - Kohne, C. H. AU - Hitre, E. AU - Zaluski, J. AU - Chang Chien, C. R. AU - Makhson, A. PY - 2009 DA - 2009// TI - Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer JO - N Engl J Med VL - 360 UR - https://doi.org/10.1056/NEJMoa0805019 DO - 10.1056/NEJMoa0805019 ID - Cutsem2009 ER - TY - JOUR AU - Douillard, J. Y. AU - Siena, S. AU - Cassidy, J. AU - Tabernero, J. AU - Burkes, R. AU - Barugel, M. PY - 2010 DA - 2010// TI - Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.27.4860 DO - 10.1200/JCO.2009.27.4860 ID - Douillard2010 ER - TY - JOUR AU - Sobrero, A. F. AU - Maurel, J. AU - Fehrenbacher, L. AU - Scheithauer, W. AU - Abubakr, Y. A. AU - Lutz, M. P. PY - 2008 DA - 2008// TI - EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.1193 DO - 10.1200/JCO.2007.13.1193 ID - Sobrero2008 ER - TY - JOUR AU - Benvenuti, S. AU - Sartore-Bianchi, A. AU - Nicolantonio, F. AU - Zanon, C. AU - Moroni, M. AU - Veronese, S. PY - 2007 DA - 2007// TI - Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies JO - Cancer Res VL - 67 UR - https://doi.org/10.1158/0008-5472.CAN-06-4158 DO - 10.1158/0008-5472.CAN-06-4158 ID - Benvenuti2007 ER - TY - JOUR AU - Sartore-Bianchi, A. AU - Nicolantonio, F. AU - Nichelatti, M. AU - Molinari, F. AU - Dosso, S. AU - Saletti, P. PY - 2009 DA - 2009// TI - Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer JO - PLoS One VL - 4 UR - https://doi.org/10.1371/journal.pone.0007287 DO - 10.1371/journal.pone.0007287 ID - Sartore-Bianchi2009 ER - TY - JOUR AU - Cutsem, E. AU - Kohne, C. H. AU - Lang, I. AU - Folprecht, G. AU - Nowacki, M. P. AU - Cascinu, S. PY - 2011 DA - 2011// TI - Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status JO - J Clin Oncol VL - 29 UR - https://doi.org/10.1200/JCO.2010.33.5091 DO - 10.1200/JCO.2010.33.5091 ID - Cutsem2011 ER - TY - JOUR AU - Bardelli, A. AU - Siena, S. PY - 2010 DA - 2010// TI - Molecular mechanisms of resistance to cetuximab and panitumumab in colorectal cancer JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.24.6116 DO - 10.1200/JCO.2009.24.6116 ID - Bardelli2010 ER - TY - JOUR AU - Rajagopalan, H. AU - Bardelli, A. AU - Lengauer, C. AU - Kinzler, K. W. AU - Vogelstein, B. AU - Velculescu, V. E. PY - 2002 DA - 2002// TI - Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status JO - Nature VL - 418 UR - https://doi.org/10.1038/418934a DO - 10.1038/418934a ID - Rajagopalan2002 ER - TY - JOUR AU - Laurent-Puig, P. AU - Cayre, A. AU - Manceau, G. AU - Buc, E. AU - Bachet, J. B. AU - Lecomte, T. PY - 2009 DA - 2009// TI - Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer JO - J Clin Oncol VL - 27 UR - https://doi.org/10.1200/JCO.2008.21.6796 DO - 10.1200/JCO.2008.21.6796 ID - Laurent-Puig2009 ER - TY - JOUR AU - Roock, W. AU - Lambrechts, D. AU - Tejpar, S. PY - 2009 DA - 2009// TI - K-ras mutations and cetuximab in colorectal cancer JO - N Engl J Med VL - 360 ID - Roock2009 ER - TY - JOUR AU - Manning, G. AU - Whyte, D. B. AU - Martinez, R. AU - Hunter, T. AU - Sudarsanam, S. PY - 2002 DA - 2002// TI - The protein kinase complement of the human genome JO - Science VL - 298 UR - https://doi.org/10.1126/science.1075762 DO - 10.1126/science.1075762 ID - Manning2002 ER - TY - JOUR AU - Blume-Jensen, P. AU - Hunter, T. PY - 2001 DA - 2001// TI - Oncogenic kinase signalling JO - Nature VL - 411 UR - https://doi.org/10.1038/35077225 DO - 10.1038/35077225 ID - Blume-Jensen2001 ER - TY - JOUR AU - Geiss, G. K. AU - Bumgarner, R. E. AU - Birditt, B. AU - Dahl, T. AU - Dowidar, N. AU - Dunaway, D. L. PY - 2008 DA - 2008// TI - Direct multiplexed measurement of gene expression with color-coded probe pairs JO - Nat Biotechnol VL - 26 UR - https://doi.org/10.1038/nbt1385 DO - 10.1038/nbt1385 ID - Geiss2008 ER - TY - JOUR AU - Amado, R. G. AU - Wolf, M. AU - Peeters, M. AU - Cutsem, E. AU - Siena, S. AU - Freeman, D. J. PY - 2008 DA - 2008// TI - Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.14.7116 DO - 10.1200/JCO.2007.14.7116 ID - Amado2008 ER - TY - JOUR AU - Roock, W. AU - Claes, B. AU - Bernasconi, D. AU - Schutter, J. AU - Biesmans, B. AU - Fountzilas, G. PY - 2010 DA - 2010// TI - Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis JO - Lancet Oncol VL - 11 UR - https://doi.org/10.1016/S1470-2045(10)70130-3 DO - 10.1016/S1470-2045(10)70130-3 ID - Roock2010 ER - TY - JOUR AU - Roock, W. AU - Piessevaux, H. AU - Schutter, J. AU - Janssens, M. AU - Hertogh, G. AU - Personeni, N. PY - 2008 DA - 2008// TI - KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdm496 DO - 10.1093/annonc/mdm496 ID - Roock2008 ER - TY - JOUR AU - Sartore-Bianchi, A. AU - Martini, M. AU - Molinari, F. AU - Veronese, S. AU - Nichelatti, M. AU - Artale, S. PY - 2009 DA - 2009// TI - PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies JO - Cancer Res VL - 69 UR - https://doi.org/10.1158/0008-5472.CAN-08-2466 DO - 10.1158/0008-5472.CAN-08-2466 ID - Sartore-Bianchi2009 ER - TY - JOUR AU - Nicolantonio, F. AU - Martini, M. AU - Molinari, F. AU - Sartore-Bianchi, A. AU - Arena, S. AU - Saletti, P. PY - 2008 DA - 2008// TI - Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.18.0786 DO - 10.1200/JCO.2008.18.0786 ID - Nicolantonio2008 ER - TY - STD TI - Kim ST, Do IG, Lee J, Sohn I, Kim KM, Kang WK. The NanoString-based multigene assay as a novel platform to screen EGFR, HER2, and MET in patients with advanced gastric cancer. Clin Transl Oncol. 2014 (In Press). ID - ref22 ER - TY - JOUR AU - Brede, G. AU - Solheim, J. AU - Prydz, H. PY - 2002 DA - 2002// TI - PSKH1, a novel splice factor compartment-associated serine kinase JO - Nucleic Acids Res VL - 30 UR - https://doi.org/10.1093/nar/gkf648 DO - 10.1093/nar/gkf648 ID - Brede2002 ER - TY - JOUR AU - Brede, G. AU - Solheim, J. AU - Troen, G. AU - Prydz, H. PY - 2000 DA - 2000// TI - Characterization of PSKH1, a novel human protein serine kinase with centrosomal, golgi, and nuclear localization JO - Genomics VL - 70 UR - https://doi.org/10.1006/geno.2000.6365 DO - 10.1006/geno.2000.6365 ID - Brede2000 ER - TY - JOUR AU - Brede, G. AU - Solheim, J. AU - Stang, E. AU - Prydz, H. PY - 2003 DA - 2003// TI - Mutants of the protein serine kinase PSKH1 disassemble the Golgi apparatus JO - Exp Cell Res VL - 291 UR - https://doi.org/10.1016/j.yexcr.2003.07.009 DO - 10.1016/j.yexcr.2003.07.009 ID - Brede2003 ER - TY - JOUR AU - Li, Z. AU - Gourguechon, S. AU - Wang, C. C. PY - 2007 DA - 2007// TI - Tousled-like kinase in a microbial eukaryote regulates spindle assembly and S-phase progression by interacting with Aurora kinase and chromatin assembly factors JO - J Cell Sci VL - 120 UR - https://doi.org/10.1242/jcs.007955 DO - 10.1242/jcs.007955 ID - Li2007 ER - TY - JOUR AU - Markert, E. K. AU - Mizuno, H. AU - Vazquez, A. AU - Levine, A. J. PY - 2011 DA - 2011// TI - Molecular classification of prostate cancer using curated expression signatures JO - Proc Natl Acad Sci U S A VL - 108 UR - https://doi.org/10.1073/pnas.1117029108 DO - 10.1073/pnas.1117029108 ID - Markert2011 ER - TY - JOUR AU - Thomas, D. C. AU - Baurley, J. W. AU - Brown, E. E. AU - Figueiredo, J. C. AU - Goldstein, A. AU - Hazra, A. PY - 2008 DA - 2008// TI - Approaches to complex pathways in molecular epidemiology: summary of a special conference of the American Association for Cancer Research JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-1690 DO - 10.1158/0008-5472.CAN-08-1690 ID - Thomas2008 ER - TY - JOUR AU - Segal, E. AU - Friedman, N. AU - Koller, D. AU - Regev, A. PY - 2004 DA - 2004// TI - A module map showing conditional activity of expression modules in cancer JO - Nat Genet VL - 36 UR - https://doi.org/10.1038/ng1434 DO - 10.1038/ng1434 ID - Segal2004 ER - TY - JOUR AU - Chin, L. AU - Hahn, W. C. AU - Getz, G. AU - Meyerson, M. PY - 2011 DA - 2011// TI - Making sense of cancer genomic data JO - Genes Dev VL - 25 UR - https://doi.org/10.1101/gad.2017311 DO - 10.1101/gad.2017311 ID - Chin2011 ER - TY - JOUR AU - Lee, J. AU - Hong, Y. S. AU - Hong, J. Y. AU - Han, S. W. AU - Kim, T. W. AU - Kang, H. J. PY - 2014 DA - 2014// TI - Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab JO - Invest New Drugs VL - 32 UR - https://doi.org/10.1007/s10637-014-0065-x DO - 10.1007/s10637-014-0065-x ID - Lee2014 ER - TY - JOUR AU - Roock, W. AU - Vriendt, V. AU - Normanno, N. AU - Ciardiello, F. AU - Tejpar, S. K. R. A. S. PY - 2011 DA - 2011// TI - PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer JO - Lancet Oncol VL - 12 UR - https://doi.org/10.1016/S1470-2045(10)70209-6 DO - 10.1016/S1470-2045(10)70209-6 ID - Roock2011 ER -